Tags

Type your tag names separated by a space and hit enter

The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
Eur Neurol. 2007; 58(2):96-9.EN

Abstract

Serum folate and vitamin B12 levels were measured in 67 consecutive Parkinson's disease patients treated either with levodopa + dopa decarboxylase inhibitor (DDC-i) plus catechol-O-methyltransferase inhibitors (COMT-i) or only with levodopa + DDC-i. The data were compared to 67 age-matched controls. Our findings show that levodopa-treated Parkinson's disease patients have low folate (p < 0.0007) and vitamin B12 levels (p < 0.0003). They also demonstrate that the addition of a COMT-i to levodopa + DDC-i treatment causes lower serum vitamin B12 (p < 0.03) and folate levels (p < 0.005) than levodopa + DDC-i treatment alone. We suggest supplementary treatment with vitamin B12 and folic acid in these situations.

Authors+Show Affiliations

Neurological Clinic, Eginition Hospital, Athens, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

17565222

Citation

Triantafyllou, N I., et al. "The Influence of Levodopa and the COMT Inhibitor On Serum Vitamin B12 and Folate Levels in Parkinson's Disease Patients." European Neurology, vol. 58, no. 2, 2007, pp. 96-9.
Triantafyllou NI, Kararizou E, Angelopoulos E, et al. The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients. Eur Neurol. 2007;58(2):96-9.
Triantafyllou, N. I., Kararizou, E., Angelopoulos, E., Tsounis, S., Boufidou, F., Evangelopoulos, M. E., Nikolaou, C., & Vassilopoulos, D. (2007). The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients. European Neurology, 58(2), 96-9.
Triantafyllou NI, et al. The Influence of Levodopa and the COMT Inhibitor On Serum Vitamin B12 and Folate Levels in Parkinson's Disease Patients. Eur Neurol. 2007;58(2):96-9. PubMed PMID: 17565222.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients. AU - Triantafyllou,N I, AU - Kararizou,E, AU - Angelopoulos,E, AU - Tsounis,S, AU - Boufidou,F, AU - Evangelopoulos,M E, AU - Nikolaou,C, AU - Vassilopoulos,D, Y1 - 2007/06/12/ PY - 2006/10/27/received PY - 2007/02/02/accepted PY - 2007/6/15/pubmed PY - 2007/9/7/medline PY - 2007/6/15/entrez SP - 96 EP - 9 JF - European neurology JO - Eur Neurol VL - 58 IS - 2 N2 - Serum folate and vitamin B12 levels were measured in 67 consecutive Parkinson's disease patients treated either with levodopa + dopa decarboxylase inhibitor (DDC-i) plus catechol-O-methyltransferase inhibitors (COMT-i) or only with levodopa + DDC-i. The data were compared to 67 age-matched controls. Our findings show that levodopa-treated Parkinson's disease patients have low folate (p < 0.0007) and vitamin B12 levels (p < 0.0003). They also demonstrate that the addition of a COMT-i to levodopa + DDC-i treatment causes lower serum vitamin B12 (p < 0.03) and folate levels (p < 0.005) than levodopa + DDC-i treatment alone. We suggest supplementary treatment with vitamin B12 and folic acid in these situations. SN - 1421-9913 UR - https://www.unboundmedicine.com/medline/citation/17565222/The_influence_of_levodopa_and_the_COMT_inhibitor_on_serum_vitamin_B12_and_folate_levels_in_Parkinson's_disease_patients_ L2 - https://www.karger.com?DOI=10.1159/000103644 DB - PRIME DP - Unbound Medicine ER -